筛选乳腺癌预防有效药物和优化剂量的机会之窗试验。

IF 7.6 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-06-09 DOI:10.1038/s41523-025-00745-8

G Aurilio, D Serrano, M Lazzeroni, A Guerrieri-Gonzaga, H Johansson, S Gandini, I M Briata, M D'Amico, S Spinaci, P Veronesi, V Galimberti, M Intra, B M Heckman-Stoddard, E Szabo, G Viale, B Bonanni, A DeCensi

{"title":"筛选乳腺癌预防有效药物和优化剂量的机会之窗试验。","authors":"G Aurilio, D Serrano, M Lazzeroni, A Guerrieri-Gonzaga, H Johansson, S Gandini, I M Briata, M D'Amico, S Spinaci, P Veronesi, V Galimberti, M Intra, B M Heckman-Stoddard, E Szabo, G Viale, B Bonanni, A DeCensi","doi":"10.1038/s41523-025-00745-8","DOIUrl":null,"url":null,"abstract":"Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"53"},"PeriodicalIF":7.6000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149318/pdf/","citationCount":"0","resultStr":"{\"title\":\"Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention.\",\"authors\":\"G Aurilio, D Serrano, M Lazzeroni, A Guerrieri-Gonzaga, H Johansson, S Gandini, I M Briata, M D'Amico, S Spinaci, P Veronesi, V Galimberti, M Intra, B M Heckman-Stoddard, E Szabo, G Viale, B Bonanni, A DeCensi\",\"doi\":\"10.1038/s41523-025-00745-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.\",\"PeriodicalId\":19247,\"journal\":{\"name\":\"NPJ Breast Cancer\",\"volume\":\"11 1\",\"pages\":\"53\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149318/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Breast Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41523-025-00745-8\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00745-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

机会之窗试验是筛选有效药物和优化乳腺癌风险降低剂量的途径。我们回顾了利用机会之窗试验筛选有效药物和优化剂量以成功降低/阻断乳腺癌风险的科学证据。低剂量他莫昔芬在机会之窗试验中进行评估，然后在iii期试验中进行验证。我们现在正在研究低剂量依西美坦的类似活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention.

查看原文本刊更多论文

Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention.

Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.